Fineline Cube

Follow:
14436 Articles
Humanwell Healthcare Receives NMPA Approval for Caplyta Generic in Schizophrenia Trial
CompanyDrug

Humanwell Healthcare Receives NMPA Approval for Caplyta Generic in Schizophrenia Trial

Clover Biopharmaceuticals Receives Termination Notice from GAVI for COVID-19 Vaccine Agreement
Company

Clover Biopharmaceuticals Receives Termination Notice from GAVI for COVID-19 Vaccine Agreement

Simcere Pharmaceutical Group Reports Steady Revenue Amid R&D Investment Shift
Company

Simcere Pharmaceutical Group Reports Steady Revenue Amid R&D Investment Shift

Henlius Biotech Reports 6.1% Revenue Growth with Strong Oncology Product Sales
Company

Henlius Biotech Reports 6.1% Revenue Growth with Strong Oncology Product Sales

Sichuan Kelun-Biotech Reports 25.5% Revenue Growth with Key Drug Approvals
Company

Sichuan Kelun-Biotech Reports 25.5% Revenue Growth with Key Drug Approvals

China's NHSA Releases 2024 Healthcare Security Bulletin Highlighting Insurance Coverage and Reimbursement
DrugMedical Device

China’s NHSA Releases 2024 Healthcare Security Bulletin Highlighting Insurance Coverage and Reimbursement

Jenscare Scientific's Ken Valve Receives NMPA Marketing Approval
CompanyMedical Device

Jenscare Scientific’s Ken Valve Receives NMPA Marketing Approval

SineuGene Therapeutics' SNUG01 Receives FDA Clearance for ALS Clinical Study
CompanyDrug

SineuGene Therapeutics’ SNUG01 Receives FDA Clearance for ALS Clinical Study

GSK's Nucala Accepted for EMA Review for COPD Treatment
CompanyDrug

GSK’s Nucala Accepted for EMA Review for COPD Treatment

Opella and JD Healthcare Collaborate to Enhance Fatty Liver Awareness in China
CompanyDeals

Opella and JD Healthcare Collaborate to Enhance Fatty Liver Awareness in China

Chongqing Zhifei Acquires 51% Stake in Chenan Bio for RMB593 Million
CompanyDeals

Chongqing Zhifei Acquires 51% Stake in Chenan Bio for RMB593 Million

Shanghai Ark Biopharmaceutical's AK0901 Meets Phase III Endpoints in ADHD Trial
CompanyDrug

Shanghai Ark Biopharmaceutical’s AK0901 Meets Phase III Endpoints in ADHD Trial